-+ 0.00%
-+ 0.00%
-+ 0.00%

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

Barchart·09/14/2026 06:00:00
Listen to the news

- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation

- Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.